Brainstorm Cell Therapeutics Inc
BCLI1.170USD
0.000
終値 09/19, 16:00（ET）15分遅れの株価
9.26M時価総額
損失額直近12ヶ月PER
詳細情報 Brainstorm Cell Therapeutics Inc 企業名
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
企業情報
企業コードBCLI
会社名Brainstorm Cell Therapeutics Inc
上場日May 28, 2003
最高経営責任者「CEO」Mr. Chaim Lebovits
従業員数27
証券種類Ordinary Share
決算期末May 28
本社所在地1325 Avenue Of Americas
都市NEW YORK
証券取引所US 'Other OTC' and Grey Market
国United States of America
郵便番号10019
電話番号12014880460
ウェブサイトhttps://brainstorm-cell.com/
企業コードBCLI
上場日May 28, 2003
最高経営責任者「CEO」Mr. Chaim Lebovits
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
44.15K
--
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Prof. Jacob A. Frenkel, Ph.D.
Prof. Jacob A. Frenkel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Menghisteab (Menghis) Bairu, M.D.
Dr. Menghisteab (Menghis) Bairu, M.D.
Independent Director
Independent Director
--
--
Dr. Anthony John (Tony) Polverino, Ph.D.
Dr. Anthony John (Tony) Polverino, Ph.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
44.15K
--
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Fri, Aug 15
更新時刻: Fri, Aug 15
株主統計
種類
株主統計
株主統計
比率
Ruck (Matthew J)
2.66%
Ness (Kevin Dean)
1.97%
Lebovits Chaim
1.94%
Caldwell Sutter Capital, Inc
1.51%
ACC International Holdings, Ltd.
1.29%
他の
90.64%
株主統計
株主統計
比率
Ruck (Matthew J)
2.66%
Ness (Kevin Dean)
1.97%
Lebovits Chaim
1.94%
Caldwell Sutter Capital, Inc
1.51%
ACC International Holdings, Ltd.
1.29%
他の
90.64%
種類
株主統計
比率
Individual Investor
10.94%
Investment Advisor
3.09%
Holding Company
1.29%
Investment Advisor/Hedge Fund
0.53%
Hedge Fund
0.10%
Research Firm
0.07%
他の
83.99%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
115
2.33M
29.32%
+762.13K
2025Q1
116
2.29M
28.90%
+743.86K
2024Q4
114
1.19M
21.02%
-226.10K
2024Q3
109
1.22M
22.61%
-265.31K
2024Q2
109
1.32M
25.54%
+439.02K
2024Q1
108
855.32K
19.26%
-132.87K
2023Q4
109
841.70K
26.44%
-125.02K
2023Q3
116
902.82K
33.14%
-178.28K
2023Q2
123
1.03M
39.20%
+17.38K
2023Q1
150
979.29K
38.21%
+5.81K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Ruck (Matthew J)
275.84K
3.47%
+275.84K
--
Nov 13, 2024
Ness (Kevin Dean)
204.00K
2.57%
-40.00K
-16.39%
Feb 14, 2024
Lebovits Chaim
200.96K
2.53%
--
--
Apr 01, 2025
Caldwell Sutter Capital, Inc
157.01K
1.98%
--
--
Mar 31, 2025
ACC International Holdings, Ltd.
133.39K
1.68%
--
--
Apr 01, 2025
Dagher (Ibrahim B.)
79.52K
1%
--
--
Apr 01, 2025
Yablonka (Uri)
68.46K
0.86%
--
--
Apr 01, 2025
Geode Capital Management, L.L.C.
58.16K
0.73%
+5.66K
+10.79%
Mar 31, 2025
Hartounian (Hartoun)
52.00K
0.66%
--
--
Apr 01, 2025
Patlis (Alla)
44.35K
0.56%
+40.00K
+919.54%
Jan 01, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
日付
種類
比率
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
